Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
Ralf Reilmann, Andrew McGarry, Igor D Grachev, Juha-Matti Savola, Beth Borowsky, Eli Eyal, Nicholas Gross, Douglas Langbehn, Robin Schubert, Anna Teige Wickenberg, Spyros Papapetropoulos, Michael Hayden, Ferdinando Squitieri, Karl Kieburtz, G Bernhard Landwehrmeyer, European Huntington's Disease Network, Christina Vangsted-Hansen (Member of study group), Lena Elisabeth Hjermind (Member of study group)
Dive into the research topics of 'Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study'. Together they form a unique fingerprint.